Skip to content

Study · Randomized controlled trial · n = 17,604 · 2024

3 results

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.

Lingvay I, Deanfield J, Kahn SE, Weeke PE, Toplak H, Scirica BM, Rydén L, Rathor N, Plutzky J, Morales C, Lincoff AM, Lehrke M and 5 more

Show all authors

Jeppesen OK, Gajos G, Colhoun HM, Cariou B, Ryan D

Diabetes care1 Aug 2024Cited by 47 (Europe PMC)

PMID38907684 (opens in a new tab)PMCIDPMC11282385 (opens in a new tab)DOI10.2337/dc24-0764 (opens in a new tab)PepBankPUB-38907684
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and atherosclerotic cardiovascular disease without diabetes, the cardiovascular risk reduction with semaglutide versus placebo did not differ across baseline HbA1c groups for the end points other than all-cause mortality.

    In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, semaglutide lowered heart risk compared with placebo similarly at all starting HbA1c levels.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular outcomes by baseline HbA1c
    Study

    n = 17,604

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    2.4 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    Cardiovascular risk reduction with semaglutide versus placebo was not shown to be different across baseline HbA1c groups and was consistent with that of the overall study for all end points, except all-cause mortality.
    2 context sentences
    Summary · context
    In people with overweight or obesity and established atherosclerotic cardiovascular disease but not diabetes, semaglutide reduced cardiovascular events irrespective of baseline HbA1c or change in HbA1c.
    Summary · context
    In SELECT, people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes were randomized to weekly semaglutide 2.4 mg or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and atherosclerotic cardiovascular disease without diabetes, all-cause mortality was the one end point where the semaglutide effect was not consistent with the overall study across baseline HbA1c groups.

    In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, semaglutide effects on all-cause deaths differed by starting HbA1c, unlike other outcomes.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedAll-cause mortality by baseline HbA1c
    Study

    n = 17,604

    Comparator
    Placebo
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    2.4 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    and was consistent with that of the overall study for all end points, except all-cause mortality.
    1 context sentence
    Summary · context
    In SELECT, people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes were randomized to weekly semaglutide 2.4 mg or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and atherosclerotic cardiovascular disease without diabetes, cardiovascular outcomes with semaglutide were consistent across subgroups of HbA1c change.

    In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, semaglutide lowered heart risk regardless of how much HbA1c changed.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular outcomes by change in HbA1c
    Study

    n = 17,604

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    2.4 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    Cardiovascular outcomes were also consistent across subgroups of HbA1c change.
    2 context sentences
    Summary · context
    In people with overweight or obesity and established atherosclerotic cardiovascular disease but not diabetes, semaglutide reduced cardiovascular events irrespective of baseline HbA1c or change in HbA1c.
    Summary · context
    In SELECT, people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes were randomized to weekly semaglutide 2.4 mg or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.